Aptus Capital Advisors LLC Makes New Investment in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Aptus Capital Advisors LLC purchased a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 139,278 shares of the company's stock, valued at approximately $1,624,000. Aptus Capital Advisors LLC owned 0.14% of Intellia Therapeutics as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in NTLA. Sterling Capital Management LLC lifted its position in shares of Intellia Therapeutics by 866.2% in the 4th quarter. Sterling Capital Management LLC now owns 3,198 shares of the company's stock worth $37,000 after purchasing an additional 2,867 shares during the period. Whipplewood Advisors LLC purchased a new stake in Intellia Therapeutics in the fourth quarter worth about $40,000. Resona Asset Management Co. Ltd. bought a new stake in Intellia Therapeutics during the 4th quarter valued at approximately $43,000. Jones Financial Companies Lllp grew its holdings in shares of Intellia Therapeutics by 140.9% during the 4th quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company's stock worth $45,000 after acquiring an additional 2,280 shares during the period. Finally, Daiwa Securities Group Inc. grew its holdings in shares of Intellia Therapeutics by 80.6% during the 4th quarter. Daiwa Securities Group Inc. now owns 5,151 shares of the company's stock worth $60,000 after acquiring an additional 2,299 shares during the period. Institutional investors own 88.77% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on NTLA shares. The Goldman Sachs Group reiterated a "sell" rating and issued a $9.00 price target on shares of Intellia Therapeutics in a research note on Friday, February 28th. Morgan Stanley cut Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and dropped their target price for the stock from $56.00 to $11.00 in a research report on Monday, January 27th. Citigroup reduced their price target on shares of Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating for the company in a research report on Friday. Wolfe Research upgraded shares of Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 price objective on the stock in a research note on Monday, April 21st. Finally, Barclays reduced their target price on shares of Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating for the company in a report on Friday, February 28th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $36.47.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA traded down $0.16 during trading hours on Friday, reaching $8.12. The stock had a trading volume of 5,135,177 shares, compared to its average volume of 2,476,091. The stock has a market capitalization of $841.09 million, a PE ratio of -1.49 and a beta of 2.33. Intellia Therapeutics, Inc. has a 52 week low of $5.90 and a 52 week high of $28.18. The company has a 50 day moving average price of $8.13 and a two-hundred day moving average price of $11.00.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.26) by $0.16. The company had revenue of $16.63 million during the quarter, compared to analysts' expectations of $11.39 million. The company's revenue was down 42.6% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.12) EPS. Equities research analysts predict that Intellia Therapeutics, Inc. will post -5.07 EPS for the current year.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.